Novo owner backs Swiss biotech company Asceneuron in $100 million round
Swiss biotech company Asceneuron said Tuesday it has raised $100 million from investors including controlling shareholder Wegovy maker Novo Nordisk to fund clinical development of its drug to treat Alzheimer’s disease.
POPULAR POSTS
Thousands under evacuation orders in California due to wildfires
November 8, 2024
EU scientists say 2024 will be the hottest year on record
November 8, 2024
LIVE STREAM